JaxBio
JaxBio
AI-powered blood test for early cancer detection and subtyping.
About
JaxBio develops a simple, fast, and highly sensitive blood test for the early diagnosis of cancer. Their technology utilizes artificial intelligence to probe thousands of cancer-specific biomarkers, enabling the identification of different cancer types and subtypes at various stages. This aims to improve cancer detection, monitoring, and treatment response prediction.
Key facts
- Website
- jaxbio.com
- Headquarters
- San Francisco, United States
- Founded
- 2021
- Employees
- 13
- Total funding
- $22M (Grant)
- Valuation
- Private
- Business model
- B2B
- Tags
- Life SciencesBiotechBloodBiomarkersOncology
Funding rounds
| Date | Round | Amount | Lead investors |
|---|---|---|---|
| 17 Jul 2024 | Grant | $3M | EU EIC Accelerator |
| 3 Jan 2023 | Grant | $9M | EU Horizon Europe |
| 1 Jan 2023 | Seed | $10M | Canaan Partners |
Tech stack
Detected on jaxbio.com, last scanned 22 Aug 2026. Run your own scan
- Frontend
- jQuery
- SEO
- Yoast SEO
- CMS / Builders
- WordPress
- Email provider
- Google Workspace
Add first review
Frequently asked
How much funding has JaxBio raised?
JaxBio has raised a total of $22M in funding. The most recent round on record is Grant.
How many employees does JaxBio have?
JaxBio has approximately 13 people on record.